Know Cancer

or
forgot password

A Clinical Study of GP73 as a HCC Early Tumor Mark


N/A
18 Years
75 Years
Open (Enrolling)
Both
Hepatocellular Carcinoma

Thank you

Trial Information

A Clinical Study of GP73 as a HCC Early Tumor Mark


Inclusion Criteria:



- A group of patients with no history of liver disease, alcohol consumption less than
40g a week, and no risk factors for viral hepatitis were enrolled from the General
Internal Medicine clinics. All subjects in this control group were documented to have
normal liver biochemistry.

- Consecutive patients with HCC and patients with HBV & HCV that were age, gender, and
race/ethnicity matched to the HCC patients were enrolled from the Liver Clinic during
this period. The diagnosis of HCC was made by histopathology, and if histopathology
was not available by two imaging modalities (ultrasound [US], magnetic resonance
imaging [MRI], or computed tomography) showing a vascular enhancing mass >2cm. HBV
infection status was based on hepatitis B surface antigen (HBsAg). HCV infection
status was based on serum HCV antibody and HCV-RNA positive.

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Authority:

China: Ethics Committee

Study ID:

PUMCH-Liver surgery -GP73

NCT ID:

NCT00902902

Start Date:

January 2008

Completion Date:

July 2009

Related Keywords:

  • Hepatocellular Carcinoma
  • Hepatocellular carcinoma
  • Carcinoma
  • Carcinoma, Hepatocellular

Name

Location

The University of ChicagoChicago, Illinois  60637